Sembragiline
- Generic Name
- Sembragiline
A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 203
- Registration Number
- NCT02104648
A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer, Alzheimer's Disease
- Interventions
- Drug: 11C-L-deprenyl-D2
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 17
- Registration Number
- NCT01701089
A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
Phase 2
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 542
- Registration Number
- NCT01677754
- Locations
- 🇺🇸
Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States
🇨🇦Vancouver Island Health Authority, Victoria, British Columbia, Canada
🇺🇸Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
A Single Dose Study of Radiolabeled RO4602522 in Healthy Volunteers
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT01631422
A Study of The Effects of Multiple Doses of Ketoconazole on Single Dose Pharmacokinetics of RO4602522 in Healthy Male Volunteers
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 34
- Registration Number
- NCT01625806
Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation.
Phase 2
Completed
- Conditions
- Smoking Cessation
- Interventions
- Drug: PlaceboDrug: EVT 302 plus open label Nicotine replacementDrug: Placebo plus open label Nicotine Replacement
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2009-05-29
- Lead Sponsor
- Evotec Neurosciences GmbH
- Target Recruit Count
- 400
- Registration Number
- NCT00738595
- Locations
- 🇩🇪
Evotec Study Site 3, Bochum, Germany
🇩🇪Evotec Study Site 9, Potsdam, Germany
🇩🇪Evotec Study Site 1, Leipzig, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath